Thank you for joining Telix at the Amer. Urol. Assn. #AUA24 in San Antonio, TX.

Telix was again pleased to present our theranostic programs at the largest meeting of urologists worldwide.

TLX591 has not received a marketing authorization in any jurisdiction.

Telix Chief Scientist Michael Wheatcroft was in QLD this week for the opening of the ARC & industry-funded AMTAR.

We’re excited to see this project launch and to partner with AIBN Research to accelerate development of novel radiopharmaceuticals in this Australian-first hub.

Telix partners with @CardinalHealth for the global clinical supply of actinium-225 (Ac-225).​

Alpha therapies are widely regarded as the next generation of radiopharmaceuticals and a priority focus area for Telix’s therapeutic pipeline expansion.​

More: bit.ly/3y6zcb7

Telix has 'gone grey' for Brain Tumour Awareness Month, to highlight the challenges faced by patients and the important work that is being done to overcome these.

Learn more about Telix's brain cancer program here: telixpharma.com/brain

#BTAM Brain Tumour Alliance Australia Cure Brain Cancer

Thank you for joining Telix at #ANZSNM2024 in Christchurch, NZ

As the premier event for nuclear medicine in Australia and NZ we were pleased to have Telix’s investigational therapeutic and diagnostic assets featured in presentations across the weekend

youtu.be/VvDf8FsQkNc

Telix has completed the acquisition of QSAM Biosciences Inc.

QSAM’s lead candidate, 153Sm-DOTMP, is a novel bone-seeking targeted radiopharmaceutical with dual potential applications of pain management of bone metastases and osteosarcoma therapy.

More: telixpharma.com/news-views/tel…

Join Telix at #AUA2024 in San Antonio!​

Oral presentations will feature TLX591, our lead rADC therapy candidate and Illuccix®, our PSMA-PET agent in prostate cancer.​

Visit booth 631 to discuss our theranostic programs in urology and click here for more: bit.ly/3WnY34q

Telix is live at #ANZSNM2024 in Christchurch, New Zealand!​

Come and meet the team at booths #29 & #30 to learn about our extensive theranostic pipeline and opportunities for collaboration. ​

More on our presence here: ​telixpharma.com/news-views/tel…

A first patient has been dosed in Australia in a Special Access Scheme for TLX250-CDx, Telix's PET imaging candidate for ccRCC.

Through this program, physicians can seek named patient access while drug approval submissions are progressed worldwide.

More: bit.ly/3JyRJ2r

Telix is supporting the Nurses Workshop at #ANZSNM2024 in collaboration with PCFA, NeuroEndocrine Cancer Australia & Peter Mac Cancer Centre

Topics include understanding the tumour microenvironment, dealing with side effects, and managing difficult conversations.

More on our website: bit.ly/4b4cUF8

Telix's investigational theranostic program for neuro-oncology will be showcased at the Nuclear Medicine and Neurooncology (NMN) in Vienna this week.​

Nelleke Tolboom and Josef Pichler, KOLs in glioma, will present TLX101 (131I-IPA) therapy and TLX101-CDx (18F-FET) imaging.​

More: nmn-society.org

Join Telix at #ANZSNM2024 this week in Christchurch, NZ.​

Our theranostic programs are featured in 5 oral abstract presentations, and we're pleased to host a Breakfast Session and once again support the Nurses Workshop.​

More about Telix at ANZSNM here: bit.ly/4b4cUF8

Telix provides notice of an Annual General Meeting of shareholders to be held on 22 May 2024 at 10.00am (Sydney time).​

For full details of the meeting including an explanatory memorandum, please visit our website here: bit.ly/3UujIqh

The FDA has granted Fast Track designation for TLX101-CDx (Pixclara™), for glioma imaging.

Telix also announces a development & commercialisation collaboration with UCSF, and PharmaLogic as commercial manufacturing partner subject to regulatory approval

bit.ly/49G7aAa

Join our breakfast at #ANZSNM2024 in Christchurch!​

Explore theranostic topics including radio antibody-drug conjugates and mobile PSMA-PET/CT in prostate cancer, kidney cancer diagnosis and treatment with radiolabelled girentuximab, and AI​.

Register: bit.ly/49EgmVZ

We welcome updated EAU Guidelines, recognising TLX250-CDx as an emerging technology for RCC management.​

This is based on evidence from Telix's Ph 3 ZIRCON trial, which met all primary and secondary endpoints, and demonstrated a 93% PPV for ccRCC.

More: bit.ly/3vGJH4e

Join Telix’s educational webinar 'Insights into Renal Cell Carcinoma' for U.S-based medical professionals in kidney cancer.

This session covers essential aspects of anatomy, physiology & pathophysiology of the renal system.

Scan QR code or register here: telixpharma.zoom.us/webinar/regist…

Telix today announces the completion of the acquisition of ARTMS Inc., a leader in “next generation” cyclotron isotope production.​

We are delighted to welcome the @artms_inc team, and their highly differentiated technologies to the Telix Group.

More: bit.ly/3xwZ9jM

Telix is pleased to announce the completion of the acquisition of IsoTherapeutics, further enhancing our in-house development capabilities and expanding our U.S. manufacturing footprint with a focus on bioconjugation and isotope processing.

More here: telixpharma.com/news-views/tel…

Telix is at the 39th Annual European Association of Urology Congress ( #EAU24 ) in Paris! Meet us at booth #F42 to learn about our broad pipeline in urology, including investigational theranostic products targeting prostate, kidney and bladder cancers: bit.ly/4aakz4R